A number of clinical trials have shown that the therapeutic effect of PD‐1/PD‐L1 immunological checkpoint inhibitors correlates with PD‐L1 expression levels in the patient's tumor microenvironment.56 In addition, considering the many side effects and the high price of immunotherapy, it is especially important to find reliable checkpoints before performing immunotherapy in esophageal cancer. Here, CD274 is linked to neoplasm.